LataMed AI Corp. (OTC: LMED), a healthcare technology company focused on digital health and artificial intelligence solutions for Latin America, announced today that it has entered into a memorandum of understanding with FARMASER to develop a customized AI and automation platform intended to support the pharmacy chain's current operations and planned expansion. The collaboration, facilitated through LataMed AI's Venezuelan operating subsidiary LATAMEDAI VE, aims to design, adapt, test, and evaluate a software platform tailored to FARMASER's operational requirements.
Under the memorandum, the parties will define technical and operational requirements, adapt the software to FARMASER's pharmacy workflows, and establish a phased development and testing process. The proposed platform may include e-commerce, prescription-management, customer-service, inventory-planning, and business-analytics functions. Additionally, LataMed AI and FARMASER will evaluate the integration of LataMed AI's CardioAI, PulmoAI, and NeuroAI models across FARMASER's three existing pharmacy locations and up to 15 planned additional locations. These AI-supported platforms are designed to assist healthcare professionals in the evaluation and management of cardiovascular, pulmonary, and neurological health information, subject to continued development, testing, regulatory requirements, and clinical protocols.
The companies emphasize that any prescription-related or AI-supported functionality would be designed to assist administrative, operational, and healthcare workflows, and would not replace the professional judgment or responsibilities of authorized pharmacists, medical professionals, or other qualified personnel. The parties are also evaluating an annual software licensing or subscription model for any commercial implementation, though the scope, timing, pricing, and other terms have not yet been finalized and remain subject to successful development, testing, and definitive documentation.
Dr. Kevin Rodan Levy, Chief Executive Officer of LataMed AI Corp., stated, "This memorandum of understanding represents an opportunity to apply our technology within an important part of the healthcare delivery ecosystem. Pharmacies play a central role in connecting patients with medications, healthcare products, and related services. Our objective is to work with FARMASER to develop a platform that supports its current operations and planned expansion while evaluating the integration of our AI-supported healthcare technologies across its pharmacy network."
Management believes that the proposed collaboration is consistent with LataMed AI's broader strategy of developing an integrated healthcare ecosystem connecting patients, healthcare professionals, pharmacies, insurers, payment providers, and other participants in healthcare delivery. The proposed FARMASER platform would also represent a potential enterprise application of the Company's technology beyond its patient-facing telemedicine services, supporting pharmacy operations, digital commerce, prescription workflows, data analysis, and the potential integration of AI-supported healthcare technologies. LataMed AI intends to develop technology infrastructure that may ultimately be adaptable to the needs of other healthcare organizations throughout Latin America.
The memorandum of understanding establishes a framework for cooperation but does not guarantee the successful completion or commercial deployment of the platform, the integration of the Company's AI-supported technologies, the execution of a definitive licensing agreement, the opening of any additional FARMASER locations, or the generation of revenue. The Company will provide additional information regarding development and potential implementation as appropriate.
For more information, visit https://latamed.ai or review the Company's filings with the U.S. Securities and Exchange Commission at www.sec.gov.
